Company Overview and News
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.39% at midday break Friday, tracking gains at regional markets, as worries over the US-China trade tensions abated somewhat.
7084 7052 GMALF 5681 BATS 4162 5134 7079 GMALY 5139 KLKBY 2445 3301 4715 7216 0900 0026 2836
KUALA LUMPUR (Sept 20): The FBM KLCI rose 0.46% at mid-morning, tracking gains at the regional markets, lifted by select index-linked blue chips.
HLFBF 7052 GMALF 1082 BATS 4162 0096 5256 5199 GMALY 5139 5258 3301 4715 0900 5208 5819 2836 HIPEF
KUALA LUMPUR (Sept 13): The FBM KLCI recovered at midday break, erasing earlier losses, climbing in line with regional peers.
HLFBF UPBMF 7036 1082 BATS 4162 0096 2089 5014 CIMDF 0166 5139 1023 1368 0900 5819 MYPRY 2836
KUALA LUMPUR (Sept 13): The FBM KLCI dipped 0.39% at mid-morning, dragged by losses at select index-linked blue chips.
HLFBF PBLOF UPBMF 7036 1082 7113 5681 TPGVF BATS 4162 0096 7087 1295 2089 5256 9334 TGLVY 5139 5258 3301 0900 5819
KUALA LUMPUR (Sept 12): The FBM KLCI dipped 0.55% at midday break today, in line with pull back at most regional markets.
4065 7036 7113 5681 TPGVF 0096 9334 6033 7277 7123 5199 TGLVY 5139 5238 PNADF 3026 0900 2836 HIPEF PNAGF 3719
KUALA LUMPUR: AEON Credit Service (M) Bhd’s annual net profit broke the RM300 million mark for the first time in the last financial year ended Feb 28, 2018 (FY18), thanks to stronger growth in the vehicle easy payment and personal financing product segments, and the group expects the good times to continue rolling into FY19.
KUALA LUMPUR (Aug 6): The FBM KLCI retreated at the midday break today, weighed by select blue chips as the local index showed some indications of a short-term consolidation.
HLFBF UPBMF 1082 7113 TPGVF 2089 9334 6033 TGLVY 0143 KLKBY 5139 2445 PNADF 5225 3301 0037 0900 Q0F IHHHF PNAGF 1929
KUALA LUMPUR (Aug 3): The FBM KLCI clawed into positive territory at the midday break today, lifted by gains at Tenaga Nasional Bhd and other select blue chips.
HLFBF 7172 2089 5014 0020 2852 KLKBY 5347 3867 TNABY MYTEF PNAGF UPBMF 1082 7765 6033 5139 2445 PNADF 4863 6645 0900 5819 MYPRY TNABF
KUALA LUMPUR (July 30): The FBM KLCI remained subdued at the midday break today, tracking its regional peers.
HLFBF APEXF 7090 8621 7036 BATS 4162 5014 5029 3026 5225 3867 1589 2739 IHHHF PNAGF 1082 5681 6033 5139 PNADF 0900 MYPRY Q0F 3719
KUALA LUMPUR (July 26): The FBM KLCI appeared to take a breather from its recent uptrend today, but not entirely perturbed by news of the offer by the entire Khazanah Nasional Bhd board to resign this morning.
HLFBF 9385 FB 1082 7113 5681 TPGVF 5031 BATS 4162 5246 9334 6033 TGLVY 5139 PNADF 5347 3301 0900 TNABY TNABF PNAGF 3719
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...